Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Sight Sciences, Inc.SGHT · Entity 5537 | Chief Legal Officer | August 10, 2026 | August 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Sight Sciences, Inc.
Report date August 10, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 181,818 |
Reported balance
After 2026-08-10 transaction · row 1
1 source rowRow 1 · 2026-08-10 · Grant · Acquired 181,818 · Balance 181,818 F1: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's 2021 Incentive Award Plan (the "2021 Plan"). The RSUs vest in four equal annual installments commencing August 10, 2027 and continuing through August 10, 2030, subject to the Reporting Person's continued service to the Issuer through each vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's 2021 Incentive Award Plan (the "2021 Plan"). The RSUs vest in four equal annual installments commencing August 10, 2027 and continuing through August 10, 2030, subject to the Reporting Person's continued service to the Issuer through each vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
NEVRO CORP
Report date April 03, 2025 · Filed April 03, 2025
Section 16 reporting ended · disclosed 2025-04-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-04-03 transaction · row 1
1 source rowRow 1 · 2025-04-03 · Disposition to issuer · Disposed 477,738 · Balance 0 F1: Pursuant to that certain Agreement and Plan of Merger, dated February 6, 2025, by and among the Issuer, Globus Medical, Inc. ("Globus") and Palmer Merger Sub, Inc., a direct, wholly owned subsidiary of Globus ("Merger Sub"), Merger Sub merged with and into the Issuer, and the Issuer became a wholly owned subsidiary of Globus upon consummation of the merger (the "Effective Time"). F2: At the Effective Time, (i) each outstanding share of Common Stock was automatically converted into the right to receive $5.85 in cash (the "Merger Consideration"), (ii) each outstanding award of restricted stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award and (b) the Merger Consideration, and (iii) each outstanding award of performance stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award, assuming that the applicable performance goals have been achieved at the greater of target and actual level of performance as determined by the compensation committee, and (b) the Merger Consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to that certain Agreement and Plan of Merger, dated February 6, 2025, by and among the Issuer, Globus Medical, Inc. ("Globus") and Palmer Merger Sub, Inc., a direct, wholly owned subsidiary of Globus ("Merger Sub"), Merger Sub merged with and into the Issuer, and the Issuer became a wholly owned subsidiary of Globus upon consummation of the merger (the "Effective Time").
F2: At the Effective Time, (i) each outstanding share of Common Stock was automatically converted into the right to receive $5.85 in cash (the "Merger Consideration"), (ii) each outstanding award of restricted stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award and (b) the Merger Consideration, and (iii) each outstanding award of performance stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award, assuming that the applicable performance goals have been achieved at the greater of target and actual level of performance as determined by the compensation committee, and (b) the Merger Consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 10, 2026 Filed Aug 18, 2026 22:08 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | GrantCommon Stock | 181,818 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-355783 · ownership.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,818 F1 · shares: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's 2021 Incentive Award Plan (the "2021 Plan"). The RSUs vest in four equal annual installments commencing August 10, 2027 and continuing through August 10, 2030, subject to the Reporting Person's continued service to the Issuer through each vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share. Read SEC document |
| April 03, 2025 Filed Apr 3, 2025 16:30 UTC | NEVRO CORP NVRO · Entity 12422 | Disposition to issuerCommon Stock | 477,738 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-050461 · ownership.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · SVP, Corp Dev and CLO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to that certain Agreement and Plan of Merger, dated February 6, 2025, by and among the Issuer, Globus Medical, Inc. ("Globus") and Palmer Merger Sub, Inc., a direct, wholly owned subsidiary of Globus ("Merger Sub"), Merger Sub merged with and into the Issuer, and the Issuer became a wholly owned subsidiary of Globus upon consummation of the merger (the "Effective Time"). F2 · price: At the Effective Time, (i) each outstanding share of Common Stock was automatically converted into the right to receive $5.85 in cash (the "Merger Consideration"), (ii) each outstanding award of restricted stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award and (b) the Merger Consideration, and (iii) each outstanding award of performance stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award, assuming that the applicable performance goals have been achieved at the greater of target and actual level of performance as determined by the compensation committee, and (b) the Merger Consideration. Read SEC document |
| March 20, 2025 Filed Mar 24, 2025 17:14 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 611 | $5.78 | $3,531.58 |
DisclosureSEC source: 0001444380-25-000052 · wk-form4_1742850887.xml · nonDerivative · entry 2 Rashid Kashif · CIK 0001725900 · SVP, Corp Dev and CLO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,462 F2 · balance_after: Includes 71,989 restricted stock units. Read SEC document |
| March 20, 2025 Filed Mar 24, 2025 17:14 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 1,136 | $0.00 | $0.00 |
DisclosureSEC source: 0001444380-25-000052 · wk-form4_1742850887.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · SVP, Corp Dev and CLO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,073 F1 · kind: Represents Performance Stock Units ("PSUs") initially granted on March 7, 2023 that were subject to a performance-based vesting condition. The Compensation Committee of the Issuer certified the achievement of the first milestone vesting condition upon which a portion of the PSUs vested. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 17:22 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 15,136 | $5.77 | $87,334.72 |
DisclosureSEC source: 0001444380-25-000039 · wk-form4_1741728129.xml · nonDerivative · entry 2 Rashid Kashif · CIK 0001725900 · SVP, Corp Dev and CLO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,937 F1 · balance_after: Includes 71,989 restricted stock units. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 17:22 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 1,758 | $5.77 | $10,143.66 |
DisclosureSEC source: 0001444380-25-000039 · wk-form4_1741728129.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · SVP, Corp Dev and CLO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,073 Read SEC document |
| March 02, 2025 Filed Mar 4, 2025 17:27 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 944 | $5.72 | $5,399.68 |
DisclosureSEC source: 0001444380-25-000028 · wk-form4_1741127245.xml · nonDerivative · entry 4 Rashid Kashif · CIK 0001725900 · SVP, Corp Dev and CLO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,831 F2 · balance_after: Includes 103,372 restricted stock units. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 17:27 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 825 | $5.72 | $4,719.00 |
DisclosureSEC source: 0001444380-25-000028 · wk-form4_1741127245.xml · nonDerivative · entry 3 Rashid Kashif · CIK 0001725900 · SVP, Corp Dev and CLO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 157,775 Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 17:27 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 392 | $5.72 | $2,242.24 |
DisclosureSEC source: 0001444380-25-000028 · wk-form4_1741127245.xml · nonDerivative · entry 2 Rashid Kashif · CIK 0001725900 · SVP, Corp Dev and CLO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,600 Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 17:27 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 742 | $0.00 | $0.00 |
DisclosureSEC source: 0001444380-25-000028 · wk-form4_1741127245.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · SVP, Corp Dev and CLO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,992 F1 · kind: Represents Performance Stock Units ("PSUs") initially granted on February 28, 2022 that were subject to a performance-based vesting condition. The Compensation Committee of the Issuer certified the achievement of the second milestone vesting condition upon which a portion of the PSUs vested. Read SEC document |
| January 04, 2025 Filed Jan 6, 2025 16:37 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 527 | $3.71 | $1,955.17 |
DisclosureSEC source: 0001444380-25-000008 · wk-form4_1736199454.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · SVP, Corp Dev and CLO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,250 F1 · balance_after: Includes 106,678 restricted stock units. Read SEC document |
| December 07, 2024 Filed Dec 9, 2024 16:23 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 1,759 | $4.19 | $7,370.21 |
DisclosureSEC source: 0001444380-24-000014 · wk-form4_1733779400.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · SVP, Corp Dev and CLO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,777 F1 · balance_after: Includes 107,570 restricted stock units. Read SEC document |
| November 28, 2024 Filed Dec 2, 2024 16:40 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 816 | $4.58 | $3,737.28 |
DisclosureSEC source: 0001444380-24-000010 · wk-form4_1733175612.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · SVP, Corp Dev and CLO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,536 F1 · balance_after: Includes 110,843 restricted stock units. Read SEC document |
| October 04, 2024 Filed Oct 8, 2024 17:32 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 479 | $4.97 | $2,380.63 |
DisclosureSEC source: 0001610717-24-000502 · form4.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · SVP, Corp Dev and CLO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,352 F1 · balance_after: Includes 112,363 restricted stock units. Read SEC document |
| September 07, 2024 Filed Sep 10, 2024 17:01 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 1,759 | $5.18 | $9,111.62 |
DisclosureSEC source: 0001610717-24-000470 · form4.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · SVP, Corp Dev and CLO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,831 F1 · balance_after: Includes 113,256 restricted stock units. Read SEC document |
| August 28, 2024 Filed Aug 30, 2024 16:59 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 817 | $5.76 | $4,705.92 |
DisclosureSEC source: 0001610717-24-000460 · form4.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · SVP, Corp Dev and CLO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 163,590 F1 · balance_after: Includes 116,530 restricted stock units. Read SEC document |
| July 04, 2024 Filed Jul 8, 2024 17:39 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 479 | $8.38 | $4,014.02 |
DisclosureSEC source: 0001610717-24-000391 · form4.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · SVP, Corp Dev and CLO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,407 F1 · balance_after: Includes 118,051 restricted stock units. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 16:15 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 1,759 | $9.27 | $16,305.93 |
DisclosureSEC source: 0001610717-24-000320 · form4.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · SVP, Corp Dev and CLO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,886 F1 · balance_after: Includes 118,943 restricted stock units. Read SEC document |
| May 28, 2024 Filed May 30, 2024 17:08 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 817 | $9.52 | $7,777.84 |
DisclosureSEC source: 0001610717-24-000268 · form4.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · SVP, Corp Dev and CLO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,645 F1 · balance_after: Includes 122,216 restricted stock units. F2 · balance_after: Includes 1,479 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 15, 2024. Read SEC document |
| April 04, 2024 Filed Apr 8, 2024 16:15 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 479 | $13.21 | $6,327.59 |
DisclosureSEC source: 0001610717-24-000204 · form4.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · SVP, Corp Dev and CLO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,983 F1 · balance_after: Includes 123,736 restricted stock units. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 16:52 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 7,045 | $15.32 | $107,929.40 |
DisclosureSEC source: 0001610717-24-000147 · form4.xml · nonDerivative · entry 2 Rashid Kashif · CIK 0001725900 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,462 F2 · balance_after: Includes 124,629 RSUs. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 16:52 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 84,326 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000147 · form4.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,507 F1 · shares: Constitutes restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. 1/3rd of the RSUs will vest on March 7, 2025 and the remainder will vest quarterly thereafter, such that all RSUs will be fully vested by the third anniversary of the grant date, subject to the Reporting Person's continued service to the issuer. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 18:23 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 425 | $14.51 | $6,166.75 |
DisclosureSEC source: 0001610717-24-000136 · form4.xml · nonDerivative · entry 2 Rashid Kashif · CIK 0001725900 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,181 F2 · balance_after: Includes 53,397 restricted stock units. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 18:23 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 743 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000136 · form4.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,606 F1 · kind: Represents Performance Stock Units ("PSUs") initially granted on February 28, 2022 that were subject to a performance-based vesting condition. The Compensation Committee of the Issuer certified the achievement of the first milestone vesting condition upon which a portion of the PSUs vested. F2 · balance_after: Includes 53,397 restricted stock units. Read SEC document |
| March 02, 2024 Filed Mar 5, 2024 16:15 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 1,790 | $14.22 | $25,453.80 |
DisclosureSEC source: 0001610717-24-000125 · form4.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,863 F1 · balance_after: Includes 53,397 restricted stock units. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 17:55 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 898 | $14.82 | $13,308.36 |
DisclosureSEC source: 0001610717-24-000104 · form4.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,653 F1 · balance_after: Includes 56,430 restricted stock units. Read SEC document |
| January 04, 2024 Filed Jan 8, 2024 17:25 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 526 | $19.39 | $10,199.14 |
DisclosureSEC source: 0001610717-24-000017 · form4.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,551 F1 · balance_after: Includes 57,951 restricted stock units. Read SEC document |
| November 28, 2023 Filed Nov 30, 2023 16:59 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 800 | $16.67 | $13,336.00 |
DisclosureSEC source: 0001610717-23-000371 · form4.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,077 F1 · balance_after: Includes 58,843 restricted stock units. Read SEC document |
| October 04, 2023 Filed Oct 6, 2023 17:14 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 1,879 | $18.07 | $33,953.53 |
DisclosureSEC source: 0001610717-23-000307 · form4.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,877 F1 · balance_after: Includes 60,363 restricted stock units. Read SEC document |
| August 28, 2023 Filed Aug 30, 2023 16:48 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 800 | $19.39 | $15,512.00 |
DisclosureSEC source: 0001610717-23-000247 · form4.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,756 F1 · balance_after: Includes 63,933 restricted stock units. Read SEC document |
| June 04, 2023 Filed Jun 6, 2023 16:41 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 450 | $28.27 | $12,721.50 |
DisclosureSEC source: 0001610717-23-000097 · form4.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,556 F1 · balance_after: Includes 65,454 restricted stock units. Read SEC document |
| May 28, 2023 Filed May 31, 2023 19:03 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 800 | $26.45 | $21,160.00 |
DisclosureSEC source: 0001610717-23-000083 · form4.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,006 F1 · balance_after: Includes 66,310 restricted stock units. F2 · balance_after: Includes 561 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 15, 2023. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 17:00 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 39,282 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-004752 · doc1.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,245 F1 · shares: Constitutes restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. 1/3rd of the RSUs will vest on March 7, 2024 and the remainder will vest quarterly thereafter, such that all RSUs will be fully vested by the third anniversary of the grant date, subject to the Reporting Person's continued service to the issuer. F2 · balance_after: Includes 67,830 RSUs. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 18:43 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 1,595 | $33.99 | $54,214.05 |
DisclosureSEC source: 0001567619-23-004535 · doc1.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,963 F1 · balance_after: Includes 28,548 restricted stock units. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 16:35 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 3,359 | $31.44 | $105,606.96 |
DisclosureSEC source: 0001567619-23-004209 · doc1.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,558 F1 · balance_after: Includes 31,580 restricted stock units. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 20:40 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 2,134 | $39.30 | $83,866.20 |
DisclosureSEC source: 0001567619-22-019159 · doc1.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,917 F1 · balance_after: Includes 37,665 restricted stock units. Read SEC document |
| October 04, 2022 Filed Oct 6, 2022 16:24 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 10,710 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-018321 · doc1.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,051 F1 · shares: Constitutes restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs will vest on October 4, 2023 and 1/12th of the remaining RSUs will vest quarterly thereafter, subject to the Reporting Person's continued service to the issuer. F2 · balance_after: Includes 41,728 RSUs. Read SEC document |
| June 04, 2022 Filed Jun 7, 2022 20:40 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 446 | $46.49 | $20,734.54 |
DisclosureSEC source: 0001567619-22-012488 · doc1.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,341 F1 · balance_after: Includes 31,018 restricted stock units. F2 · balance_after: Reflects the adjusted total which includes the purchase of 261 shares under the Issuer's Employee Stock Purchase Plan on May 13, 2022. Read SEC document |
| May 09, 2022 Filed May 10, 2022 17:44 UTC | NEVRO CORP NVRO · Entity 12422 | PurchaseCommon Stock | 2,250 | $44.50 | $100,126.13 |
DisclosureSEC source: 0001567619-22-009957 · doc1.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,526 F1 · balance_after: Includes 31,874 restricted stock units. Read SEC document |
| March 11, 2022 Filed Mar 14, 2022 19:51 UTC | NEVRO CORP NVRO · Entity 12422 | PurchaseCommon Stock | 1,500 | $64.04 | $96,067.20 |
DisclosureSEC source: 0001567619-22-006942 · doc1.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,276 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $63.93 to $64.07. The reporting person undertakes to provide the Issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchase at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 31,874 restricted stock units. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 19:13 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 1,591 | $71.27 | $113,390.57 |
DisclosureSEC source: 0001567619-22-006435 · doc1.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,776 F1 · balance_after: Includes 31,874 restricted stock units. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:01 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 18,249 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-006142 · doc1.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,367 F1 · shares: Constitutes restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs will vest on February 28, 2023 and the remainder will vest quarterly thereafter, subject to the Reporting Person's continued service to the issuer. F2 · balance_after: Includes 34,905 RSUs. Read SEC document |
| January 02, 2022 Filed Jan 4, 2022 18:06 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 1,423 | $81.07 | $115,362.61 |
DisclosureSEC source: 0001567619-22-000352 · doc1.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,118 F1 · balance_after: Includes 16,656 restricted stock units. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 15:03 UTC | NEVRO CORP NVRO · Entity 12422 | PurchaseCommon Stock | 2,000 | $101.05 | $202,100.00 |
DisclosureSEC source: 0001567619-21-020354 · doc1.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,541 F1 · balance_after: Includes 19,156 restricted stock units. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 17:22 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 2,137 | $116.26 | $248,447.62 |
DisclosureSEC source: 0001567619-21-019291 · doc1.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,541 F1 · balance_after: Includes 19,156 restricted stock units. Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 16:52 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 449 | $148.77 | $66,797.73 |
DisclosureSEC source: 0001567619-21-011841 · doc1.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,678 F1 · balance_after: Includes 23,219 restricted stock units. F2 · balance_after: Includes 148 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 14, 2021. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 19:19 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 640 | $168.11 | $107,590.40 |
DisclosureSEC source: 0001567619-21-005671 · doc1.xml · nonDerivative · entry 2 Rashid Kashif · CIK 0001725900 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,979 F2 · balance_after: Includes 24,075 RSUs. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 19:19 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 7,136 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-005671 · doc1.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,619 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 25% of the RSUs vest annually on March 2 of each year, beginning March 2, 2022, subject to the Reporting Person's continued service to the issuer. F2 · balance_after: Includes 24,075 RSUs. Read SEC document |
| January 02, 2021 Filed Jan 5, 2021 17:27 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 1,365 | $173.10 | $236,281.50 |
DisclosureSEC source: 0001567619-21-000326 · doc1.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,483 F1 · balance_after: Includes 18,187 restricted stock units. Read SEC document |
| November 01, 2020 Filed Nov 3, 2020 16:32 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 2,192 | $149.21 | $327,068.32 |
DisclosureSEC source: 0001567619-20-018618 · doc1.xml · nonDerivative · entry 1 Rashid Kashif · CIK 0001725900 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,848 F1 · balance_after: Includes 20,687 restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.